Abbott Laboratories vs. Amneal Pharmaceuticals, Inc. Class A Common Stock
ABT
Abbott Laboratories
$102.83 +0.58%
VS AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock
$17.01 +0.83%
Abbott Laboratories (ABT) comes out ahead, leading on 7 of 9 compared factors.
Size & Scale
| ABT | AMRX | |
|---|---|---|
| Market Cap | $176.90 billion | $5.92 billion |
| Revenue (TTM) | $46.59 billion | $3.12 billion |
| Net Income (TTM) | $5.42 billion | $215.32 million |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | AMRX | |
|---|---|---|
| P/E Ratio | 33.28 | 34.71 |
| Price / Book | 3.42 | 179.40 |
| Price / Sales | 3.80 | 1.90 |
ABT leads on 2 of 3 valuation factors.
Profitability
| ABT | AMRX | |
|---|---|---|
| Net Margin | 11.65% | 6.91% |
| Return on Equity | 10.48% | 652.01% |
ABT and AMRX split the profitability factors evenly.
Dividend
| ABT | AMRX | |
|---|---|---|
| Dividend Yield | 2.45% | — |
| Payout Ratio | 81.55 | — |
ABT and AMRX split the dividend factors evenly.
Risk & Sentiment
| ABT | AMRX | |
|---|---|---|
| Short Interest | 0.57% | 2.39% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, AMRX overview, AMRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.